ArticleDiscover oncology2025
Machine learning multiomics Deciphers GRHL2 associated tumor microenvironment evolution guiding precision therapeutics in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Grainyhead-like 2 (GRHL2) has been implicated in various cancers, but its role in breast cancer (BRCA) remains poorly understood. This study aims to comprehensively characterize the prognostic and immunological significance of GRHL2 in BRCA using multi-omics data. We analyzed single-cell RNA sequencing (scRNA-seq) data and multiple bulk RNA-seq datasets. Tumor cells were identified using InferCNV, and prognostic genes were refined via CoxBoost regression. GRHL2 was identified as a risk factor associated with poor survival in multiple cohorts. Functional enrichment analysis revealed its involvement in key oncogenic pathways. Furthermore, GRHL2 expression correlated with immune infiltration patterns, immunomodulator expression, and somatic mutation profiles. Drug sensitivity analysis suggested potential therapeutic agents targeting GRHL2-related pathways. Collectively, our findings highlight GRHL2 as a promising prognostic biomarker for risk stratification and a candidate therapeutic target, with specific implications for guiding immunotherapy and targeted treatment strategies in BRCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.